



(51) International Patent Classification:

C07H 1/00 (2006.01)

C07H 19/16 (2006.01)

C07H 19/06 (2006.01)

C07H 21/00 (2006.01)

(21) International Application Number:

PCT/US2019/033847

(22) International Filing Date:

23 May 2019 (23.05.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/676,196

24 May 2018 (24.05.2018)

US

(71) Applicant: VALKYRIE PHARMACEUTICS, INC.

[US/US]; 1211 Sunset Plaza Drive, Los Angeles, California 90069 (US).

(72) Inventor: BERZ, David; c/o Valkyrie Pharmaceuticals, Inc.,

1211 Sunset Plaza Drive, Los Angeles, California 90069 (US).

(74) Agent: SOLOWAY, Norman, P. et al.; c/o HAYES

SOLOWAY PC, 4640 E. Skyline Drive, Tucson, Arizona 85718 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: METHODS AND FORMULATIONS FOR THE TREATMENT OF OBESITY AND OBESITY-RELATED METABOLIC DISEASES





FIG. 1

(57) Abstract: An oligo- or polynucleotide analogue having one or more structures of the general formula: where B is a pyrimidine or purine nucleic acid base, or an analogue thereof, is used for treating obesity-related metabolic diseases.

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*